Patents Assigned to Bayer Healthcare AG
  • Regulation of human adenylate cyclase
    Patent number: 7205135
    Abstract: Reagents which regulate human adenylate cyclase and reagents which bind to human adenylate cyclase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, peripheral and central nervous system disorders, disorders of the genito-urinary system including but not limited to benign prostatic hyperplasia and urinary incontinence, obesity, COPD and diabetes.
    Type: Grant
    Filed: November 12, 2001
    Date of Patent: April 17, 2007
    Assignee: Bayer HealthCare AG
    Inventor: Zhimin Zhu
  • Diagnostics and therapeutics for diseases associated with kallikrein 9 (klk9)
    Publication number: 20070081997
    Abstract: The invention provides a human KLK9 which is associated with the hematological diseases, cardiovascular diseases, neurological diseases, metabolic diseases, urological diseases, cancer disorders, inflammation disorders, dermatological diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, neurological diseases, metabolic diseases, urological diseases, cancer disorders, inflammation disorders, dermatological diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK9 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: August 17, 2004
    Publication date: April 12, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Stefanie Polej
  • Substituted imidazotriazines
    Patent number: 7202243
    Abstract: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: April 10, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Martin Hendrix, David Brückner, Arno Friedl, Irene Gerlach, Volker Hinz, Jörg Keldenich, Frank Mauler, Maria Niewöhner, legal representative, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteegen, Özkan Yalkinoglu, Ulrich Niewöhner, deceased
  • 1,4-dihydro-1,4-diphenylpyridine derivatives
    Patent number: 7199136
    Abstract: The invention relates to novel 1,4-dihydro-1,4-diphenylpyridine derivatives of formula (I) wherein the variable groups are as defined in the text and claims. Processes for their preparation, pharmaceutical compositions containing them, and methods of treatment of inflammatory processes, expecially chronic obstructive pulmonary diseases, using them are also disclosed and claimed.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: April 3, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Heike Gielen-Haertwig, Volkhart Min-Jian Li, Ulrich Rosentreter, Karl-Heinz Schlemmer, Swen Allerheiligen, Kevin Nash, Mary Fitzgerald
  • Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 85 (gpr85)
    Publication number: 20070071753
    Abstract: The invention provides a human GPR85 which is associated with the cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR85 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 19, 2004
    Publication date: March 29, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts, Holger Summer
  • Substituted dihydroquinazolines
    Patent number: 7196086
    Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: March 27, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Jürgen Reefschläger, Rudolf Schohe-Loop, Frank Süssmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jörg Keldenich, Dieter Lang, Peter Nell
  • Method for the production of 4-(4-aminophenyl)-3-morpholinone
    Publication number: 20070066611
    Abstract: The present invention relates to a process for preparing 4-(4-aminophenyl)-3-morpholinone by reacting 4-(4-nitrophenyl)-3-morpholinone with hydrogen in the presence of a hydrogenation catalyst, characterized in that the reaction is effected in an aliphatic alcohol.
    Type: Application
    Filed: September 9, 2004
    Publication date: March 22, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Christian Thomas, Mathias Berwe, Alexander Straub
  • Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
    Publication number: 20070065801
    Abstract: The invention provides a human 5-HT4 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT4 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 12, 2004
    Publication date: March 22, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Regulation of human caspase-1-like protease
    Patent number: 7192732
    Abstract: Screening methods to identify candidate therapeutic agents using a newly identified human caspases-1-like protease.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: March 20, 2007
    Assignee: Bayer Healthcare AG
    Inventor: Shyam Ramakrishnan
  • Substituted isoindoles and their use thereof
    Patent number: 7189738
    Abstract: The invention relates to coagulation of the blood. Disclosed are novel compounds of formula (I), a method for the production of these compounds, pharmaceutical compositions containing them, and methods of using them for the prevention and/or treatment of various diseases.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: March 13, 2007
    Assignee: Bayer Healthcare AG
    Inventors: Alexander Straub, Thomas Lampe, Jens Pohlmann, Susanne Rohrig, Elisabeth Perzborn, Karl-Heinz Schlemmer
  • Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
    Publication number: 20070053913
    Abstract: The invention provides a human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: September 16, 2004
    Publication date: March 8, 2007
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
    Publication number: 20070053911
    Abstract: The invention provides a human PAR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, neurological disorders, urological disorders, hematological diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PAR2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 26, 2004
    Publication date: March 8, 2007
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
  • Direct observation of molecular modifications in biological test systems by measuring flourescence lifetime
    Publication number: 20070042500
    Abstract: The invention relates to a method for directly detecting the modification of a molecule containing a fluorescent dye by measuring the fluorescence lifetime.
    Type: Application
    Filed: October 5, 2004
    Publication date: February 22, 2007
    Applicant: Bayer Healthcare AG
    Inventors: Frans-Josef Meyer-Almes, Gabriele Wirtz
  • Isolated berovin photoprotein and use thereof
    Publication number: 20070042375
    Abstract: The invention relates to the photoprotein berovin, to its nucleotide and amino acid sequences and to the activity and use of the photoprotein berovin.
    Type: Application
    Filed: August 13, 2004
    Publication date: February 22, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Svetlana Markova, Ludmila Burakova, Ludmila Frank, Eugene Vysotski
  • Regulation of human serine/threonine kinase
    Patent number: 7179629
    Abstract: Reagents that regulate human serine/threonine kinase and reagents which bind to human serine/threonine kinase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, diabetes, neurological disorders, cardiovascular disorders, musculo-skeletal disorders, inflammatory disorders, genitourological disorders, and respiratory disorders (e.g., asthma and COPD).
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: February 20, 2007
    Assignee: Bayer Healthcare AG
    Inventor: Jiing-Ren Liou
  • Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor1(adipor1)
    Publication number: 20070037226
    Abstract: The invention provides a human AdipoR1 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: September 16, 2004
    Publication date: February 15, 2007
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggermeier, Andreas Geerts
  • Test methods for determining the intracellular concentration of cyclic nucleotides
    Publication number: 20070031834
    Abstract: The invention relates to methods for the quantitative optical analysis of the intracellular concentration of the cyclic nucleotides cGMP and cAMP, said methods using cell lines which express a combination of certain CNG channels, a calcium-sensitive photoprotein, and different target proteins for which modulators are to be found, in a recombinant manner. The cell lines modified in this way are suitable for high-throughput screening (HTS and uHTS) and can be used to identify medicaments which influence the activity of receptors or enzymes participating in the composition or decomposition of the cyclic nucleotides cGMP and cAMP.
    Type: Application
    Filed: March 6, 2004
    Publication date: February 8, 2007
    Applicant: Bayer HealthCare AG
    Inventor: Frank Wunder
  • Organic anion transporting (oat)-like protein ust3-like1 and uses thereof
    Publication number: 20070031938
    Abstract: The present invention is directed to a polynucleotide sequence of a novel organic anion transporting (OAT)-like protein UST3-like1. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand. The invention also provides the human UST3-LIKE1 associated with the gastrointestinal and liver diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cardiovascular diseases as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds useful for the modulation of said diseases.
    Type: Application
    Filed: March 4, 2004
    Publication date: February 8, 2007
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Carbamate-substituted pyrazolopyridines
    Patent number: 7173037
    Abstract: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: February 6, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Cristina Alonso-Alija, Erwin Bischoff, Klaus Münter, Johannes-Peter Stasch, Elke Stahl, Stefan Weigand, Achim Feurer
  • Hydroxy-tetrahydro-naphthalenylurea derivatives
    Publication number: 20070027187
    Abstract: This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Application
    Filed: February 5, 2004
    Publication date: February 1, 2007
    Applicant: Bayer HealthCare AG
    Inventors: Takeshi Yura, Muneto Mogi, Hiroshi Fujishima, Klaus Urbahns, Tsutomu Masuda, Yasuhiro Tsukimi, Masaomi Tajimi, Noriyuki Yamamoto, Nagahiro Yoshida, Toshiya Moriwaki